TROP2 Targeted Therapy: Module

CME

TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: February 22, 2024

Expiration: February 21, 2025

Komal Jhaveri
Komal Jhaveri, MD, FACP

Activity

Progress
1 2
Course Completed

Overall Conclusions

Although sacituzumab govitecan is currently the only FDA-approved TROP-2‒directed ADC for patients with HER2-negative breast cancer, several novel ADCs targeting TROP-2, such as Dato-DXd and SKB264, are emerging and in the clinical pipeline. Of these emerging TROP-2‒directed ADCs, Dato-DXd is the most advanced in clinical development. In general, ADCs such as T-DXd and sacituzumab govitecan are effective for patients with relapsed/refractory breast cancer and have shifted the treatment paradigm for these patients. These agents have changed the treatment landscape for patients with HR-positive and HR-negative/HER2-negative advanced breast cancer. Based on their efficacy in the advanced disease setting, ADCs are now being investigated up front in the early-stage breast cancer setting.

As the field continues to evolve and expand with the approval of more ADCs, it will be important to better understand the mechanisms of resistance to these agents so that we can optimally select and sequence ADCs to maximize treatment benefit for our patients.